NASDAQ:RKDA Arcadia Biosciences (RKDA) Stock Forecast, Price & News $3.25 +0.06 (+1.88%) (As of 09/22/2023 08:52 PM ET) Add Compare Share Share Today's Range$3.10▼$3.2650-Day Range$3.19▼$5.4352-Week Range$3.10▼$24.75Volume9,100 shsAverage Volume76,351 shsMarket Capitalization$3.61 millionP/E RatioN/ADividend YieldN/APrice Target$15.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Arcadia Biosciences MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside361.6% Upside$15.00 Price TargetShort InterestHealthy0.10% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$2,382 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($7.27) to ($3.92) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.19 out of 5 stars 3.5 Analyst's Opinion Consensus RatingArcadia Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.00, Arcadia Biosciences has a forecasted upside of 361.6% from its current price of $3.25.Amount of Analyst CoverageArcadia Biosciences has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.10% of the float of Arcadia Biosciences has been sold short.Short Interest Ratio / Days to CoverArcadia Biosciences has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Arcadia Biosciences has recently decreased by 87.23%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldArcadia Biosciences does not currently pay a dividend.Dividend GrowthArcadia Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RKDA. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Arcadia Biosciences this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for RKDA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arcadia Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,382.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 2.00% of the stock of Arcadia Biosciences is held by insiders.Percentage Held by InstitutionsOnly 12.61% of the stock of Arcadia Biosciences is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Arcadia Biosciences are expected to grow in the coming year, from ($7.27) to ($3.92) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcadia Biosciences is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcadia Biosciences is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcadia Biosciences has a P/B Ratio of 0.10. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Arcadia Biosciences (NASDAQ:RKDA) StockArcadia Biosciences, Inc. produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring. The company was incorporated in 2002 and is headquartered in Dallas, Texas.Read More RKDA Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RKDA Stock News HeadlinesSeptember 18, 2023 | americanbankingnews.comArcadia Biosciences (NASDAQ:RKDA) Now Covered by Analysts at StockNews.comAugust 12, 2023 | benzinga.comArcadia Biosciences Stock (NASDAQ:RKDA), Earnings Estimates, EPS, and RevenueSeptember 25, 2023 | Chaikin Analytics (Ad)His system isolated NVIDIA - Here's His Next Buy.Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.August 11, 2023 | finance.yahoo.comQ2 2023 Arcadia Biosciences Inc Earnings CallAugust 11, 2023 | finance.yahoo.comArcadia Biosciences (RKDA) Reports Q2 Loss, Misses Revenue EstimatesAugust 10, 2023 | finance.yahoo.comArcadia Biosciences (RKDA) Announces Second-Quarter and First-Half 2023 Financial Results and Business HighlightsAugust 9, 2023 | finance.yahoo.comOrion (OEC) Misses Q2 Earnings and Revenue EstimatesJuly 28, 2023 | finance.yahoo.comArcadia Biosciences (RKDA) Announces Date of Second Quarter 2023 Financial Results and Business Highlights Conference CallSeptember 25, 2023 | Chaikin Analytics (Ad)Buy This Stock for AI Tidal Wave (not NVDA)The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.July 25, 2023 | msn.comHC Wainwright & Co. Reiterates Arcadia Biosciences (RKDA) Buy RecommendationJuly 24, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Its Buy Rating for Arcadia Biosciences (RKDA)July 21, 2023 | bizjournals.comDavis-based Arcadia Biosciences engages investment bank Lake Street Capital to explore strategic optionsJuly 20, 2023 | marketwatch.comArcadia Biosciences Shares Rise 6.8% After Beginning Strategic ReviewJuly 20, 2023 | benzinga.comArcadia Biosciences Seeks Strategic Options; Warns On Challenging Economic HeadwindsJuly 20, 2023 | msn.comArcadia Biosciences stock jumps as company explores possible saleJuly 20, 2023 | uk.finance.yahoo.comRKDA - Arcadia Biosciences, Inc.July 20, 2023 | marketwatch.comArcadia Biosciences to Explore Potential Sale, Merger in Strategic ReviewJuly 20, 2023 | finance.yahoo.comArcadia Biosciences (RKDA) Announces Strategic ReviewJuly 17, 2023 | finance.yahoo.comArcadia Biosciences (RKDA) Launches GoodWheat™ into the Breakfast Category with New Better-For-You Pancake & Waffle Mixes and Single-Serve Quikcakes™July 6, 2023 | msn.comArcadia Biosciences (RKDA) Price Target Decreased by 7.89% to 17.85May 12, 2023 | marketwatch.com8-K: Arcadia Biosciences, Inc.May 12, 2023 | finance.yahoo.comQ1 2023 Arcadia Biosciences Inc Earnings CallMay 11, 2023 | seekingalpha.comArcadia Biosciences reports Q1 resultsMay 11, 2023 | finance.yahoo.comArcadia Biosciences (RKDA) Announces First Quarter 2023 Financial Results from Operations and Business HighlightsMay 8, 2023 | finance.yahoo.comGoodWheat™ Pasta Named "Best New Product" By Retail Dietitians Business AllianceApril 28, 2023 | finance.yahoo.comArcadia Biosciences (RKDA) Announces Date of First Quarter 2023 Financial Results and Business Highlights Conference CallApril 15, 2023 | msn.comHC Wainwright & Co. Maintains Arcadia Biosciences (RKDA) Buy RecommendationSee More Headlines Receive RKDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcadia Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address RKDA Company Calendar Last Earnings8/10/2023Today9/24/2023Next Earnings (Estimated)11/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Agricultural production - crops Sub-IndustryN/A SectorBasic Materials Current SymbolNASDAQ:RKDA CUSIPN/A CIK1469443 Webwww.arcadiabio.com Phone(530) 756-7077Fax530-756-7027Employees30Year FoundedN/APrice Target and Rating Average Stock Price Forecast$15.00 High Stock Price Forecast$20.00 Low Stock Price Forecast$10.00 Forecasted Upside/Downside+361.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($21.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-15,380,000.00 Net Margins-271.33% Pretax Margin-272.78% Return on Equity-69.76% Return on Assets-46.47% Debt Debt-to-Equity RatioN/A Current Ratio5.70 Quick Ratio4.93 Sales & Book Value Annual Sales$9.96 million Price / Sales0.36 Cash FlowN/A Price / Cash FlowN/A Book Value$33.92 per share Price / Book0.10Miscellaneous Outstanding Shares1,110,000Free Float1,086,000Market Cap$3.61 million OptionableNot Optionable Beta0.98 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Stanley E. Jacot Jr. (Age 53)Pres, CEO & Director Comp: $527.9kMs. Laura Pitlik (Age 49)Chief Marketing Officer Comp: $374kMr. Thomas J. Schaefer (Age 47)CFO & Corp. Sec. Ms. Belinda YaoVP of OperationsMr. Brian SchafferSr. VP of SalesKey CompetitorsIT Tech PackagingNYSE:ITPVenator MaterialsNYSE:VNTRQVenator MaterialsNYSE:VNTRTantechNASDAQ:TANHAustin GoldNYSE:AUSTView All CompetitorsInsidersThomas J SchaeferBought 649 shares on 8/4/2023Total: $2,381.83 ($3.67/share)Stanley Jacot JrBought 5,000 shares on 5/30/2023Total: $21,550.00 ($4.31/share)Thomas J SchaeferBought 700 shares on 2/1/2023Total: $161.00 ($0.23/share)View All Insider Transactions RKDA Stock - Frequently Asked Questions Should I buy or sell Arcadia Biosciences stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arcadia Biosciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RKDA shares. View RKDA analyst ratings or view top-rated stocks. What is Arcadia Biosciences' stock price forecast for 2023? 1 Wall Street analysts have issued 1 year price objectives for Arcadia Biosciences' stock. Their RKDA share price forecasts range from $10.00 to $20.00. On average, they predict the company's share price to reach $15.00 in the next twelve months. This suggests a possible upside of 361.6% from the stock's current price. View analysts price targets for RKDA or view top-rated stocks among Wall Street analysts. How have RKDA shares performed in 2023? Arcadia Biosciences' stock was trading at $0.2710 at the beginning of the year. Since then, RKDA stock has increased by 1,099.2% and is now trading at $3.2499. View the best growth stocks for 2023 here. Are investors shorting Arcadia Biosciences? Arcadia Biosciences saw a decrease in short interest in the month of August. As of August 31st, there was short interest totaling 600 shares, a decrease of 87.2% from the August 15th total of 4,700 shares. Based on an average trading volume of 38,900 shares, the short-interest ratio is presently 0.0 days. Approximately 0.1% of the company's stock are short sold. View Arcadia Biosciences' Short Interest. When is Arcadia Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. View our RKDA earnings forecast. How were Arcadia Biosciences' earnings last quarter? Arcadia Biosciences, Inc. (NASDAQ:RKDA) announced its earnings results on Thursday, August, 10th. The basic materials company reported ($2.64) earnings per share for the quarter, beating analysts' consensus estimates of ($4.92) by $2.28. The basic materials company earned $1.39 million during the quarter, compared to the consensus estimate of $1.43 million. Arcadia Biosciences had a negative trailing twelve-month return on equity of 69.76% and a negative net margin of 271.33%. When did Arcadia Biosciences' stock split? Arcadia Biosciences shares reverse split on the morning of Wednesday, January 24th 2018. The 1-20 reverse split was announced on Tuesday, January 23rd 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 23rd 2018. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What guidance has Arcadia Biosciences issued on next quarter's earnings? Arcadia Biosciences updated its second quarter 2023 earnings guidance on Thursday, July, 20th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.30 million-$1.50 million, compared to the consensus revenue estimate of $1.82 million. What is Matthew Plavan's approval rating as Arcadia Biosciences' CEO? 1 employees have rated Arcadia Biosciences Chief Executive Officer Matthew Plavan on Glassdoor.com. Matthew Plavan has an approval rating of -100% among the company's employees. This puts Matthew Plavan in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Arcadia Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arcadia Biosciences investors own include Bionano Genomics (BNGO), ADMA Biologics (ADMA), Zosano Pharma (ZSAN), Gran Tierra Energy (GTE), Matinas BioPharma (MTNB), Organigram (OGI), Pennsylvania Real Estate Investment Trust (PEI), Novan (NOVN), CNBX Pharmaceuticals (CNBX) and Enerplus (ERF). When did Arcadia Biosciences IPO? (RKDA) raised $66 million in an IPO on Friday, May 15th 2015. The company issued 8,200,000 shares at a price of $8.00 per share. Credit Suisse, J.P. Morgan and Piper Jaffray acted as the underwriters for the IPO. What is Arcadia Biosciences' stock symbol? Arcadia Biosciences trades on the NASDAQ under the ticker symbol "RKDA." How do I buy shares of Arcadia Biosciences? Shares of RKDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Arcadia Biosciences' stock price today? One share of RKDA stock can currently be purchased for approximately $3.25. How much money does Arcadia Biosciences make? Arcadia Biosciences (NASDAQ:RKDA) has a market capitalization of $3.61 million and generates $9.96 million in revenue each year. The basic materials company earns $-15,380,000.00 in net income (profit) each year or ($21.36) on an earnings per share basis. How can I contact Arcadia Biosciences? Arcadia Biosciences' mailing address is 202 COUSTEAU PLACE SUITE 105, DAVIS CA, 85018. The official website for the company is www.arcadiabio.com. The basic materials company can be reached via phone at (530) 756-7077, via email at ir@arcadiabio.com, or via fax at 530-756-7027. This page (NASDAQ:RKDA) was last updated on 9/25/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcadia Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.